about
Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors.Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congenersPurine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modificationsExtended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists.Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonistsTruncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition ElementEngagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic painJohn Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y ReceptorsAnti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart.Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches.Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo EfficacyStructure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.Controlling murine and rat chronic pain through A3 adenosine receptor activationEfficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain.Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.Metabolic mapping of A3 adenosine receptor agonist MRS5980Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activityOptimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane SubstitutionsStructure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonistsCharacterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor.Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine.Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonistsModulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles.Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.Asymmetric synthesis of cyclopropyl-fused 2'-C-methylcarbanucleosides as potential anti-HCV agents.Stereoselective synthesis of 1'-functionalized-4'-thionucleosides.Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active site of S-adenosylhomocysteine hydrolase.Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists.Stereoselective synthesis of 2'-C-methyl-cyclopropyl-fused carbanucleosides as potential anti-HCV agents.
P50
Q27345188-C799C491-514B-4834-818A-809C5ADAA905Q28539094-FFFBA223-B2FD-486B-BFA7-8E0538B365AAQ30793386-7B89434B-304A-4C8B-B0EC-3D62CF704C7DQ31039936-F8A2B05C-E261-4794-8337-B7986216BE3FQ33638882-3AB412D9-A4BF-4C34-95FF-3C2BB1E5EC3BQ33754704-23D21B82-8ED0-47CB-8994-05EE30FC7480Q34109265-FE975F2F-79FA-4924-87DB-9614FEFE358DQ34152737-15D44734-49EE-4D75-9D25-01AE36036ADEQ34701441-FC811B66-C40E-4712-AE8A-1884D47DEAD7Q34746993-1B5BB9C1-F56B-4E39-ABA6-95CDEC2F2D49Q35029175-D5F6B5BB-0E02-4BD7-8075-96BAF16F698EQ35048339-9DBB700B-AD72-4E8D-8880-AE0D222A4723Q35165684-2ED41B61-3925-4089-9754-763215B5EA0DQ35423661-C3588DED-8CFC-4151-8ED1-0981B2B5954DQ35580301-024877E7-AD5B-498D-8E0C-F1835507B8BFQ35754166-7784973E-1E4D-4C44-9EC2-36E3D54723A6Q35795478-756E9694-FAE6-46AC-8A04-36A67035D128Q35825817-A26FB7F4-C137-4E32-9682-1DF206409135Q35844532-28620AED-FBA8-4A77-836C-94AA64B5CB24Q35896690-428578A3-A448-4625-AD85-EAF05CB3C5EDQ35913037-BCEC939F-C34A-4D44-9419-87E58DC513BAQ35930748-41C7FF6E-D0B9-4679-8F84-4DD7C444EC2CQ36021597-67E65CD7-AAFB-42EE-8DFB-48BB27347975Q36088970-11FE3911-1278-4B05-B302-2A78B52295E7Q36146803-A09566CE-305D-4177-BAA7-E4CE6D33DA55Q36294092-CCCF45A2-5CC0-43A9-A650-DFF0056684C0Q36343219-D09EE845-7D29-4447-A961-CB45A06EF5AEQ36377951-8CE63389-98FF-42C1-83C2-AE8206DE82D5Q36546173-F39F6CB9-117A-4ADE-B131-9215FC633B73Q36704325-0071BE6B-8BC0-4BFF-99E2-7BB32382A984Q36733500-378C3D0E-F46D-4D2F-BDF9-0B0EF969264AQ36740173-0E6A62EC-8324-4872-ACF9-F0E1A566053DQ36821548-676CB6BC-1F6E-4ADD-9D3B-B3B5451834D5Q37062531-D3172B6E-1AA9-4CE6-A398-A28AD4C94CF2Q37381136-4154218C-41C0-43C5-A0D3-E59D9F263862Q38503248-13B6C696-2D4E-4E3F-9A50-8722D1D029A3Q38503252-6A9B0167-57F9-4CA2-BEC7-0B29BD56339EQ38505437-18BBC6DF-B5D8-4813-ACD3-225B274189CBQ38505609-967E9832-EB1F-4546-BF6E-9DA457845B48Q38508341-83ED4706-9030-4721-9A53-3BC3950D2078
P50
name
Dilip K Tosh
@en
type
label
Dilip K Tosh
@en
prefLabel
Dilip K Tosh
@en